Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule

P. W. Cobb, K. A. Havlin, J. G. Kuhn, J. B. Craig, G. S. Harman, J. S. Luther, J. N. Turner, G. R. Weiss, D. A. Tweedy, J. Koeller, R. L. Tuttle, V. S. Lucas, W. Wargin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 388 mg/m2. Neurologic toxicity was dose-limiting in that trial and correlated with the attainment of a threshold plasma concentration of >4.5 μg/ml. In this study we treated 15 patients with escalating doses of crisnatol from 450 mg/m2 to 900 mg/m2 administered at a rate of 50 mg/m2/hr over 9, 12, 15, and 18 hours. Toxicity was mild to moderate at all dose levels. However, serious central nervous system effects were noted in one patient at 900 mg/m2 over 18 hours whose plasma level was 6.5 μg/ml. This study has demonstrated higher total doses of crisnatol can be given if the drug is administered as a prolonged infusion in an attempt to avoid high plasma levels of the agent.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalSelective Cancer Therapeutics
Volume7
Issue number2
StatePublished - 1991

Fingerprint

Appointments and Schedules
Antineoplastic Agents
Nervous System
Central Nervous System
Pharmaceutical Preparations
crisnatol

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Cobb, P. W., Havlin, K. A., Kuhn, J. G., Craig, J. B., Harman, G. S., Luther, J. S., ... Wargin, W. (1991). Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule. Selective Cancer Therapeutics, 7(2), 85-91.

Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule. / Cobb, P. W.; Havlin, K. A.; Kuhn, J. G.; Craig, J. B.; Harman, G. S.; Luther, J. S.; Turner, J. N.; Weiss, G. R.; Tweedy, D. A.; Koeller, J.; Tuttle, R. L.; Lucas, V. S.; Wargin, W.

In: Selective Cancer Therapeutics, Vol. 7, No. 2, 1991, p. 85-91.

Research output: Contribution to journalArticle

Cobb, PW, Havlin, KA, Kuhn, JG, Craig, JB, Harman, GS, Luther, JS, Turner, JN, Weiss, GR, Tweedy, DA, Koeller, J, Tuttle, RL, Lucas, VS & Wargin, W 1991, 'Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule', Selective Cancer Therapeutics, vol. 7, no. 2, pp. 85-91.
Cobb PW, Havlin KA, Kuhn JG, Craig JB, Harman GS, Luther JS et al. Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule. Selective Cancer Therapeutics. 1991;7(2):85-91.
Cobb, P. W. ; Havlin, K. A. ; Kuhn, J. G. ; Craig, J. B. ; Harman, G. S. ; Luther, J. S. ; Turner, J. N. ; Weiss, G. R. ; Tweedy, D. A. ; Koeller, J. ; Tuttle, R. L. ; Lucas, V. S. ; Wargin, W. / Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule. In: Selective Cancer Therapeutics. 1991 ; Vol. 7, No. 2. pp. 85-91.
@article{43182d4ec92e4138bd49e85d54e45f26,
title = "Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule",
abstract = "Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 388 mg/m2. Neurologic toxicity was dose-limiting in that trial and correlated with the attainment of a threshold plasma concentration of >4.5 μg/ml. In this study we treated 15 patients with escalating doses of crisnatol from 450 mg/m2 to 900 mg/m2 administered at a rate of 50 mg/m2/hr over 9, 12, 15, and 18 hours. Toxicity was mild to moderate at all dose levels. However, serious central nervous system effects were noted in one patient at 900 mg/m2 over 18 hours whose plasma level was 6.5 μg/ml. This study has demonstrated higher total doses of crisnatol can be given if the drug is administered as a prolonged infusion in an attempt to avoid high plasma levels of the agent.",
author = "Cobb, {P. W.} and Havlin, {K. A.} and Kuhn, {J. G.} and Craig, {J. B.} and Harman, {G. S.} and Luther, {J. S.} and Turner, {J. N.} and Weiss, {G. R.} and Tweedy, {D. A.} and J. Koeller and Tuttle, {R. L.} and Lucas, {V. S.} and W. Wargin",
year = "1991",
language = "English (US)",
volume = "7",
pages = "85--91",
journal = "Selective Cancer Therapeutics",
issn = "1043-0733",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule

AU - Cobb, P. W.

AU - Havlin, K. A.

AU - Kuhn, J. G.

AU - Craig, J. B.

AU - Harman, G. S.

AU - Luther, J. S.

AU - Turner, J. N.

AU - Weiss, G. R.

AU - Tweedy, D. A.

AU - Koeller, J.

AU - Tuttle, R. L.

AU - Lucas, V. S.

AU - Wargin, W.

PY - 1991

Y1 - 1991

N2 - Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 388 mg/m2. Neurologic toxicity was dose-limiting in that trial and correlated with the attainment of a threshold plasma concentration of >4.5 μg/ml. In this study we treated 15 patients with escalating doses of crisnatol from 450 mg/m2 to 900 mg/m2 administered at a rate of 50 mg/m2/hr over 9, 12, 15, and 18 hours. Toxicity was mild to moderate at all dose levels. However, serious central nervous system effects were noted in one patient at 900 mg/m2 over 18 hours whose plasma level was 6.5 μg/ml. This study has demonstrated higher total doses of crisnatol can be given if the drug is administered as a prolonged infusion in an attempt to avoid high plasma levels of the agent.

AB - Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 388 mg/m2. Neurologic toxicity was dose-limiting in that trial and correlated with the attainment of a threshold plasma concentration of >4.5 μg/ml. In this study we treated 15 patients with escalating doses of crisnatol from 450 mg/m2 to 900 mg/m2 administered at a rate of 50 mg/m2/hr over 9, 12, 15, and 18 hours. Toxicity was mild to moderate at all dose levels. However, serious central nervous system effects were noted in one patient at 900 mg/m2 over 18 hours whose plasma level was 6.5 μg/ml. This study has demonstrated higher total doses of crisnatol can be given if the drug is administered as a prolonged infusion in an attempt to avoid high plasma levels of the agent.

UR - http://www.scopus.com/inward/record.url?scp=0025999604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025999604&partnerID=8YFLogxK

M3 - Article

C2 - 1754731

AN - SCOPUS:0025999604

VL - 7

SP - 85

EP - 91

JO - Selective Cancer Therapeutics

JF - Selective Cancer Therapeutics

SN - 1043-0733

IS - 2

ER -